Verrica Pharmaceuticals Inc.
VRCA
$6.84
$0.6310.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.02M | 5.09M | 14.34M | 12.70M | 3.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.02M | 5.09M | 14.34M | 12.70M | 3.44M |
| Cost of Revenue | 4.75M | 3.92M | 3.31M | 2.34M | 2.72M |
| Gross Profit | 274.00K | 1.17M | 11.03M | 10.36M | 718.00K |
| SG&A Expenses | 9.99M | 8.12M | 9.40M | 8.85M | 8.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.74M | 12.04M | 12.72M | 11.19M | 11.57M |
| Operating Income | -9.72M | -6.95M | 1.63M | 1.51M | -8.13M |
| Income Before Tax | -9.68M | -8.07M | -274.00K | 204.00K | -9.74M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.68M | -8.07M | -274.00K | 204.00K | -9.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.68M | -8.07M | -274.00K | 204.00K | -9.74M |
| EBIT | -9.72M | -6.95M | 1.63M | 1.51M | -8.13M |
| EBITDA | -9.60M | -6.83M | 1.74M | 1.64M | -7.99M |
| EPS Basic | -0.45 | -0.57 | -0.03 | 0.02 | -1.03 |
| Normalized Basic EPS | -0.28 | -0.28 | -0.02 | 0.01 | -0.64 |
| EPS Diluted | -0.45 | -0.57 | -0.03 | 0.02 | -1.03 |
| Normalized Diluted EPS | -0.28 | -0.28 | -0.02 | 0.01 | -0.64 |
| Average Basic Shares Outstanding | 21.31M | 14.11M | 9.49M | 9.49M | 9.48M |
| Average Diluted Shares Outstanding | 21.31M | 14.11M | 9.49M | 9.49M | 9.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |